Remove Bioequivalency Remove Branding Remove Production
article thumbnail

How to Identify Branded Drugs with a Low Likelihood of Generic Entry as Targets for In-Licensing

Drug Patent Watch

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.

article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

FDA Law Blog

Among other things, DPDs functions included: Facilitating the development, clearance, and publication of Product-Specific Guidances (PSGs). About one third of these PSGs are for complex products and many reflect what OGD and DPD learned about the science of equivalence from GDUFA-funded regulatory science research.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Do generics producers have what it takes to tackle complex and specialty drugs?

Pharmaceutical Technology

But this also reflects a wider trend within the broader market, which is moving towards complex biological and non-biological products, he adds. Unlike biosimilars, it is simpler for small molecule specialty generics to establish equivalence to their branded forms, explains Vasquez.

Drugs 298
article thumbnail

The Role of Scientific Expertise in Generic Drug Development

Drug Patent Watch

Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts. This knowledge is critical in designing bioequivalence studies and ensuring that generic drugs have the same therapeutic effect as the brand-name drug.

article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

The ANDA must demonstrate bioequivalence to the Reference Listed Drug (RLD), which is the original brand-name drug approved for marketing in Japan. Pharmaceutical companies must navigate the PMDA’s requirements and guidelines to ensure successful approval and marketing of their products.

article thumbnail

The drug industry continues to dare regulation

World of DTC Marketing

Reportedly, the cost of production for molnupiravir stands at about $17.74. A new study estimates the causal effects of coupons for branded drugs without bioequivalent generics using variation in coupon introductions over time and comparing differential responses across enrollees in commercial and Medicare Advantage plans.

article thumbnail

Innovative Approaches to Generic Drug Development: Case Studies

Drug Patent Watch

Why Generic Drugs Matter Generic drugs are the Robin Hoods of the pharmaceutical world, stealing from the rich (brand-name drugs) and giving to the poor (our wallets). They offer the same therapeutic benefits as their brand-name counterparts but at a fraction of the cost. But how do companies develop these cost-effective alternatives?